The Oncology Institute Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is The Oncology Institute Inc 's ROA in the second quarter of 2026?
The Oncology Institute Inc recorded a cumulative net loss of $-27 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -16.04%.

However, within the Healthcare sector 339 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3450, from total ROA ranking in the first quarter of 2026 at 4286.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	11.54 %	2.58 %	10.25 %	6.58 %	3.75 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-27	-33	-50	-49	-51
Return On Assets (TTM)	-16.04 %	-20 %	-30.86 %	-30.7 %	-32.69 %
TOI's Total Ranking	# 3450	# 4286	# 3762	# 3791	# 3852
Total Assets (TTM) in million	178	168	165	164	160
Seq. Total Assets Change	5.95 %	2.17 %	0.63 %	2.39 %	-2.56 %
Seq. Net Income Change	-	-	-	-	-

TOI's 5 Years Annual ROA >> Back to TOI Management Effectiveness >> Compare TOI ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 34
Sector	# 340
Overall	# 3343

Return On Assets Statistics
High	Average	Low
5.14 %	-15.32 %	-30.86 %
(Dec 31 2022)		(Dec 31 2025)

Financial Statements
The Oncology Institute Inc 's Assets	$ 178 million	TOI's Balance sheet
The Oncology Institute Inc 's Income	$ -8 million	Quarterly TOI's Income Statement
TOI's Income by Division		See TOI's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	10.25 %	-18.17 %	-23.86 %	17.82 %	-11.96 %
Total Assets in million	165	149	183	240	203
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-50	-53	-68	0	-11
Annual Return On Assets	-30.55 %	-35.49 %	-37.19 %	0.03 %	-5.37 %

TOI's 5 Years Annual ROA >> Back to TOI Management Effectiveness >> Compare TOI ROA to its Competitors

More Return On Assets Ratios
TOI's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TOI's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TOI's Competitors
Subscribers only: Roa for The Oncology Institute Inc 's Suppliers
Subscribers only: Return On Assets for TOI's Customers

You may also want to know
TOI's Roi	TOI's Inventory Turnover Ratio	TOI's Growth Rates	TOI's Dividend Comparisons
	TOI's Profitability Ratios	TOI's Asset Turnover Ratio	TOI's Dividend Growth
TOI's Roe	TOI's Valuation Ratios	TOI's Financial Strength Ratios	TOI's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T15:35:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.